Carbapenem Consumption and Rate of carbapenemresistant gram-negative bacteria: results from the Sicilian Surveillance System
Keywords:
Carbapenem-resistance, public health, resistance rates, surveillance, carbapenem antibiotic consumptionAbstract
Background. In the last decades, multidrug-resistant gram-negative bacteria have been increasing and they are involved in severe healthcare associated infections. In treating drug-resistant gram-negative bacterial infections, carbapenems are generally administered as a last choice. However, the rate of carbapenemresistant bacteria is constantly increasing the last years. The aim of the present study is to describe the relationship between the rate of carbapenem-resistant gram-negative bacteria and antibiotic consumption intensity.
Study design. In 2017, the Sicilian Region implemented a regional surveillance system to describe and analyze consumption of antibiotics in hospital settings, as well as prevalence of antibiotic resistant microorganisms.
Methods. Resistance data were retrospectively collected from routinary clinical antimicrobial susceptibility tests. Resistance rates (RRs) of carbapenems were calculated and Spearman’s correlation analysis was performed to investigate the relationship between annual antibiotic consumption and rate of carbapenem resistance.
Results. In 2015, the overall prevalence of carbapenem-resistant Klebsiella pneumoniae isolates was 43.9 %, and was positively correlated with beta-lactam consumption (R=0.529, p<0.01), and with carbapenem consumption (R=0.364, p<0.05). In 2016, the overall prevalence of carbapenem-resistant Klebsiella pneumoniae isolates was 53.8 %, and was positively correlated with carbapenem antibiotic consumption (R=0.364, p<0.05). In 2017, the overall prevalence of carbapenem-resistant Klebsiella pneumoniae isolates was 58.7 %, and was significantly positively correlated with carbapenem antibiotic consumption (R=0.427, p<0.05). In 2015, the overall prevalence of carbapenem-resistant Escherichia coli isolates was 6.5 %, and was significantly positively correlated with antibiotic consumption for the ATC class J01 (i.e., antibacterial for systemic use) (R=0.402, p<0.05).
Conclusion. The results of the present study highlight the need for comprehensive strategies targeting the appropriate use of antibiotics and infection control measures.
References
1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2012. In: Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden: ECDC, 2013.
2. World Health Organization (WHO). Antimicrobial Resistance Global Report on Surveillance 2014. Geneva, Switzerland: WHO, 2014.
3. Serra-Burriel M, Keys M, Campillo-Artero C, et al. Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcareassociated infections in adults: Systematic review and meta-analysis. PLoS One 2020; 15(1):
e0227139. doi: 10.1371/journal.pone.0227139.
4. Agodi A, Auxilia F, Barchitta M, et al. Antibiotic consumption and resistance: results of the SPINUTI project of the GISIO-SItI. Epidemiol Prev 2015; 39(4 Suppl 1): 94-8.
5. Agodi A, Auxilia F, Barchitta M, et al. Trends, risk factors and outcomes of healthcareassociated infections within the Italian network SPIN-UTI. J Hosp Infect 2013; 84(1): 52-8. doi: 10.1016/j.jhin.2013.02.012. Epub 2013 Mar 30.
6. Masia MD, Barchitta M, Liperi G, et al. Validation of intensive care unit-acquired infection surveillance in the Italian SPIN-UTI network. J Hosp Infect 2010; 76(2): 139-42. doi: 10.1016/j. jhin.2010.05.013. Epub 2010 Jul 14.
7. Agodi A, Auxilia F, Barchitta M, et al. Building a benchmark through active surveillance of intensive care unit-acquired infections: the Italian network SPIN-UTI. J Hosp Infect 2010; 74(3): 258-65. doi: 10.1016/j.jhin.2009.08.015. Epub 2009 Nov 14.
8. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 2014; 20(9): 821-30. doi: 10.1111/14690691.12719.
9. Agodi A, Barchitta M, Quattrocchi A, et al. Antibiotic trends of Klebsiella pneumoniae and Acinetobacter baumannii resistance indicators in an intensive care unit of Southern Italy, 20082013. Antimicrob Resist Infect Control 2015; 4:
43. doi: 10.1186/s13756-015-0087-y.
10. Barchitta M, Cipresso R, Giaquinta L, et al. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Int J Hyg Environ Health 2009; 212(3): 330-7. doi: 10.1016/j.ijheh.2008.07.001. Epub 2008 Sep 3.
11. Agodi A, Voulgari E, Barchitta M, et al. Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp Infect 2014; 86(4): 260-6. doi: 10.1016/j. jhin.2014.02.001. Epub 2014 Feb 20.
12. Zarrilli R, Di Popolo A, Bagattini M, et al. Clonal spread and patient risk factors for acquisition of extensively drug-resistant Acinetobacter baumannii in a neonatal intensive care unit in Italy.
J Hosp Infect 2012; 82(4): 260-5. doi: 10.1016/j. jhin.2012.08.018. Epub 2012 Oct 24.
13. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18(2): 306-25.
doi: 10.1128/CMR.18.2.306-325.2005.
14. Castro-Sánchez E, Moore LS, Husson F, Holmes AH. What are the factors driving antimicrobial resistance? Perspectives from a public event in London, England. BMC Infect Dis 2016; 16(1): 465. doi: 10.1186/s12879-016-1810-x.
15. Arepyeva MA, Kolbin AS, Sidorenko SV, et al. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. J Glob Antimicrob Resist 2017; 8: 148-56. doi: 10.1016/j.jgar.2016.11.010. Epub 2017 Feb 3.
16. Stapleton PJ, Lundon DJ, McWade R, et al. Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005-2014. Ir J Med Sci 2017; 186(3): 733-41. doi: 10.1007/ s11845-016-1538-z. Epub 2017 Jan 4.
17. Tammer I, Geginat G, Lange S, et al. [Antibiotic Consumption and the Development of Antibiotic Resistance in Surgical Units]. German. Zentralbl Chir 2016; 141(1): 53-61. doi: 10.1055/s-00331351087. Epub 2014 Apr 28.
18. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and metaanalysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 2014; 14: 13. doi: 10.1186/1471-2334-14-13.
19. Valencia C, Hammami N, Agodi A, et al. Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey. Antimicrob Resist Infect Control 2016; 5: 49. doi: 10.1186/ s13756-016-0139-y.
20. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 2010; 25(6): 343-8. doi: 10.1177/0885066610377975.
21. World Health Organization (WHO). Guidelines for the Prevention and Control of CarbapenemResistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities. Geneva: WHO, 2017.
22. Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 2016; 22(Suppl 1): S9-14. doi: 10.1016/j.cmi.2016.01.001.
23. Barchitta M, Quattrocchi A, Maugeri A, et al. Antibiotic Consumption and Resistance during a 3-Year Period in Sicily, Southern Italy. Int J Environ Res Public Health 2019; 16(13). doi:
10.3390/ijerph16132253. Epub 2019 Jun 26.
24. Piano Nazionale di Contrasto dell’Antimicrobico-Resistenza 2017–2020 (PNCAR)
2017. [Available on: http://www.salute.gov.it/ imgs/C_17_pubblicazioni_2660_allegato.pdf. [Last accessed: 2020, Nov 21].
25. Regione Siciliana. Assessorato della Salute. DASOE. Programma Regionale di Sorveglianza e Controllo delle ICA. Available on: https:// www.qualitasiciliassr.it/?q=infezioni-correlateassistenza [Last accessed: 2020, Nov 21].
26. Barchitta M, Quattrocchi A, Maugeri A, et al. The “Obiettivo Antibiotico” Campaign on Prudent Use of Antibiotics in Sicily, Italy: The Pilot Phase. Int J Environ Res Public Health 2020; 17(9): 3077. doi: 10.3390/ijerph17093077.
27. Bebell LM, Muiru AN. Antibiotic use and emerging resistance: how can resource-limited countries turn the tide? Glob Heart 2014; 9(3): 347-58. doi: 10.1016/j.gheart.2014.08.009. Epub 2014 Oct 31.
28. Tao W, Ivanovska V, Schweickert B, Muller A. Proxy indicators for antibiotic consumption; surveillance needed to control antimicrobial resistance. Bull World Health Organ 2019; 97(1): 3-3A. doi: 10.2471/BLT.18.227348.
29. World Health Organization (WHO). Ten Threats to Global Health in 2019. Available on: https:// www.who.int/ emergencies/ten-threats-toglobal-health-in-2019. Last accessed 2020 Mar 24.
30. World Health Organization WHO). Global
Priority List of Antibiotic Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 2017. Available on: https:// www.who.int/medicines/publications/WHOPPL-Short_Summary_25Feb [Last accessed: 2020 Nov 21].
31. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control 2019; 8: 137. doi: 10.1186/s13756-019-0590-7.
32. Tabak YP, Sung AH, Ye G, Vankeepuram L, Gupta V, McCann E. Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections. J Hosp Infect 2019; 102(1): 37-44.
33. Rodriguez-Acevedo AJ, Lee XJ, Elliott TM, Gordon LG. Hospitalization costs for patients colonized with carbapenemase-producing Enterobacterales during an Australian outbreak. J Hosp Infect 2020; 105(2): 146-53. Hospitalization costs for patients colonized with carbapenemase-producing Enterobacterales during an Australian outbreak. J Hosp Infect 2020; 105(2): 146-53. doi: 10.1016/j.jhin.2020.03.009. Epub 2020 Mar 13.
34. The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: Effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23: 106-8. doi: 10.1086/502018.
35. Tian L, Tan R, Chen Y, et al. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob Resist Infect Control 2016; 5: 48. doi: 10.1186/s13756-016-0145-0.
36. European Centre for Disease Prevention and
Control (ECDC). Surveillance of Antimicrobial Resistance in Europe. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden: ECDC, 2017.
37. Wang R, Yang Q, Zhang S, Hong Y, Zhang M, Jiang S. Trends and correlation of antibiotic susceptibility and antibiotic consumption at a large teaching hospital in China (2007-2016): a surveillance study. Ther Clin Risk Manag 2019; 15: 1019-27. doi: 10.2147/TCRM.S210872.
38. Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect
Control 2018; 7: 137. doi: 10.1186/s13756-018 -0430-1.
39. Hu F, Chen S, Xu X, et al. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. J Med Microbiol 2012; 61(Pt 1): 132-6. doi: 10.1099/ jmm.0.036483-0. Epub 2011 Sep 8.
40. World Health Organization (WHO). Global Action Plan on Antimicrobial Resistance. WHO, 2015. Available on: https://www.who. int/antimicrobial-resistance/publications/globalaction-plan/en/ [Last accessed: 2020 Nov 21].
41. Agodi A, Barchitta M, Gianninò V, et al. Burkholderia cepacia complex in cystic fibrosis and non-cystic fibrosis patients: identification of a cluster of epidemic lineages. J Hosp Infect 2002; 50(3): 188-95. doi: 10.1053/jhin.2001.1160.
42. Donelli G, De Paoli P, Fadda G, et al. A multicenter study on central venous catheter-associated infections in Italy. J Chemother 2001; 13 Spec No 1(1): 251-62. doi: 10.1179/joc.2001.13.
Supplement-2.251.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.